Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government

IF 3.1 4区 医学 Q1 ECONOMICS Applied Health Economics and Health Policy Pub Date : 2023-07-03 DOI:10.1007/s40258-023-00816-6
Karel H. van der Pol, Mohamad Aljofan, Olivier Blin, Jan H. Cornel, Gerard A. Rongen, Aurélie-Gaëlle Woestelandt, Michael Spedding
{"title":"Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government","authors":"Karel H. van der Pol,&nbsp;Mohamad Aljofan,&nbsp;Olivier Blin,&nbsp;Jan H. Cornel,&nbsp;Gerard A. Rongen,&nbsp;Aurélie-Gaëlle Woestelandt,&nbsp;Michael Spedding","doi":"10.1007/s40258-023-00816-6","DOIUrl":null,"url":null,"abstract":"<div><p>Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it ‘on label’. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.</p></div>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Health Economics and Health Policy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40258-023-00816-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it ‘on label’. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
仿制药的药物再利用:挑战和政府的潜在作用。
药物再利用是指在原始适应症范围之外的适应症中识别现有药物或活性物质的新用途的过程。药物再利用具有重要优势,包括减少开发时间和成本,并可能节省大量社会医疗成本。然而,目前的仿制药再利用研究在获得研究资金方面面临着许多挑战。此外,无论重新利用试验是否成功,商业方往往出于财务原因对寻求上市授权缺乏兴趣,学术研究人员也缺乏知识、时间和资金。因此,重新利用药物的新适应症通常不会使其“出现在标签上”。我们建议大幅增加对仿制药再利用研究的公共资金,包括在试验成功后用于上市许可程序的资金,以及减少再利用仿制药上市许可程序中的监管负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Applied Health Economics and Health Policy
Applied Health Economics and Health Policy Economics, Econometrics and Finance-Economics and Econometrics
CiteScore
6.10
自引率
2.80%
发文量
64
期刊介绍: Applied Health Economics and Health Policy provides timely publication of cutting-edge research and expert opinion from this increasingly important field, making it a vital resource for payers, providers and researchers alike. The journal includes high quality economic research and reviews of all aspects of healthcare from various perspectives and countries, designed to communicate the latest applied information in health economics and health policy. While emphasis is placed on information with practical applications, a strong basis of underlying scientific rigor is maintained.
期刊最新文献
Social Costs of Smoking in the Czech Republic. Economic Evaluations of Robotic-Assisted Surgery: Methods, Challenges and Opportunities. Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis. The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years. Measuring the Impact of Medical Cannabis Law Adoption on Employer-Sponsored Health Insurance Costs: A Difference-in-Difference Analysis, 2003–2022
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1